Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

QuintilesIMS
Merck
McKinsey
Express Scripts
AstraZeneca
Daiichi Sankyo
Harvard Business School
McKesson
Accenture

Generated: May 28, 2018

DrugPatentWatch Database Preview

Details for Patent: 6,987,101

« Back to Dashboard

Summary for Patent: 6,987,101
Title:Therapeutic gestagens for the treatment of premenstrual dysphoric disorder
Abstract:A method for treating premenstrual dysphoric disorder comprises administering a therapeutically effective amount of a gestagen. Optionally, a natural or synthetic estrogen is also administered. In one embodiment, the gestagen and optional estrogen are administered during the luteal phase of the female menstrual cycle, preferably from day 10 to day 28.
Inventor(s): Nashed; Norman (Munchen, DE)
Assignee: Schering Aktiengesellschaft (Berlin, DE)
Application Number:09/619,493
Patent Litigation and PTAB cases: See patent lawsuits and PTAB cases for patent 6,987,101
Patent Claim Types:
see list of patent claims
Use; Delivery;

Drugs Protected by US Patent 6,987,101

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Foreign Priority and PCT Information for Patent: 6,987,101

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
Germany196 54 609Dec 20, 1996

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Harvard Business School
QuintilesIMS
Colorcon
Boehringer Ingelheim
Daiichi Sankyo
McKesson
McKinsey
Queensland Health
Argus Health

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.